|
1
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asia-Pacific Working Party on Prevention
of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma
in the Asia-Pacifc region: consensus statements. J Gastroenterol
Hepatol. 25:657–663. 2010. View Article : Google Scholar
|
|
4
|
Yuen MF, Hou JL and Chutaputti A; Asia
Pacific Working Party on Prevention of Hepatocellular Carcinoma:
Hepatocellular carcinoma in the Asia pacific region. J
Gastroenterol Hepatol. 24:346–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schwartz ME and Shrager B: Surgical
resection for hepatocellular carcinoma in the noncirrhotic: the
Western experience. Recent Results Cancer Res. 190:85–100. 2013.
View Article : Google Scholar
|
|
6
|
Yang Y, Nagano H, Ota H, et al: Patterns
and clinicopathologic features of extrahepatic recurrence of
hepatocellular carcinoma after curative resection. Surgery.
141:196–202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang ZY, Ye SL, Liu YK, et al: A decade’s
studies on metastasis of hepatocellular carcinoma. J Cancer Res
Clin Oncol. 130:187–196. 2004. View Article : Google Scholar
|
|
8
|
Yang LY, Tao YM, Ou DP, Wang W, Chang ZG
and Wu F: Increased expression of Wiskott-Aldrich syndrome protein
family verprolin-homologous protein 2 correlated with poor
prognosis of hepatocellular carcinoma. Clin Cancer Res.
12:5673–5679. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okuda K: Hepatocellular carcinoma:
clinicopathological aspects. J Gastroenterol Hepatol. 12:S314–S318.
1997. View Article : Google Scholar
|
|
10
|
Tandon P and Garcia-Tsao G: Prognostic
indicators in hepatocellular carcinoma: a systematic review of 72
studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Bisceglie AM: Issues in screening and
surveillance for hepatocellular carcinoma. Gastroenterology.
127(Suppl 1): S104–S107. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daniele B, Bencivenga A, Megna AS and
Tinessa V: α-fetoprotein and ultrasonography screening for
hepatocellular carcinoma. Gastroenterology. 127(Suppl 1):
S108–S112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farinati F, Marino D, De Giorgio M, et al:
Diagnostic and prognostic role of α-fetoprotein in hepatocellular
carcinoma: both or neither? Am J Gastroenterol. 101:524–532. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minegishi M, Tachibana K, Sato T, Iwata S,
Nojima Y and Morimoto C: Structure and function of Cas-L, a 105-kD
Crk-associated substrate-related protein that is involved in β1
integrin-mediated signaling in lymphocytes. J Exp Med.
184:1365–1375. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Law SF, Estojak J, Wang B, Mysliwiec T,
Kruh G and Golemis EA: Human enhancer of filamentation 1, a novel
p130cas-like docking protein, associates with focal
adhesion kinase and induces pseudohyphal growth in Saccharomyces
cerevisiae. Mol Cell Biol. 16:3327–3337. 1996.PubMed/NCBI
|
|
16
|
Kumar S, Tomooka Y and Noda M:
Identification of a set of genes with developmentally
down-regulated expression in the mouse brain. Biochem Biophys Res
Commun. 185:1155–1161. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tikhmyanova N, Little JL and Golemis EA:
CAS proteins in normal and pathological cell growth control. Cell
Mol Life Sci. 67:1025–1048. 2010. View Article : Google Scholar :
|
|
18
|
Minn AJ, Gupta GP, Siegel PM, et al: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Natarajan M, Stewart JE, Golemis EA, et
al: HEF1 is a necessary and specific downstream effector of FAK
that promotes the migration of glioblastoma cells. Oncogene.
25:1721–1732. 2006. View Article : Google Scholar
|
|
20
|
Kim M, Gans JD, Nogueira C, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xue YZ, Sheng YY, Liu ZL, et al:
Expression of NEDD9 in pancreatic ductal adenocarcinoma and its
clinical significance. Tumour Biol. 34:895–899. 2013. View Article : Google Scholar
|
|
22
|
Guerrero MS, Parsons JT and Bouton AH: Cas
and NEDD9 contribute to tumor progression through dynamic
regulation of the cytoskeleton. Genes Cancer. 3:371–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Astier A, Manié SN, Law SF, et al:
Association of the Cas-like molecule HEF1 with CrkL following
integrin and antigen receptor signaling in human B-cells: potential
relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma.
28:65–72. 1997.
|
|
24
|
Lucas JT Jr, Salimath BP, Slomiany MG and
Rosenzweig SA: Regulation of invasive behavior by vascular
endothelial growth factor is HEF1-dependent. Oncogene.
29:4449–4459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kong C, Wang C, Wang L, et al: NEDD9 is a
positive regulator of epithelial-mesenchymal transition and
promotes invasion in aggressive breast cancer. PLoS One.
6:e226662011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tikhmyanova N and Golemis EA: NEDD9 and
BCAR1 negatively regulate E-cadherin membrane localization, and
promote E-cadherin degradation. PLoS One. 6:e221022011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thao le B, Vu HA, Yasuda K, et al: Cas-L
was over-expressed in imatinib-resistant gastrointestinal stromal
tumor cells. Cancer Biol Ther. 8:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagasue N: Liver resection for
hepatocellular carcinoma: indications, techniques, complications,
and prognostic factors. J Hepatobiliary Pancreat Surg. 5:7–13.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC
and Hsu HC: High α-fetoprotein level correlates with high stage,
early recurrence and poor prognosis of hepatocellular carcinoma:
significance of hepatitis virus infection, age, p53 and β-catenin
mutations. Int J Cancer. 112:44–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trevisani F, D’Intino PE, Morselli-Labate
AM, et al: Serum α-fetoprotein for diagnosis of hepatocellular
carcinoma in patients with chronic liver disease: influence of
HBsAg and anti-HCV status. J Hepatol. 34:570–575. 2001. View Article : Google Scholar : PubMed/NCBI
|
